Sorry, you need to enable JavaScript to visit this website.

Hospira, Inc., Issues A Voluntary Nationwide Recall for one lot of BACTERIOSTATIC WATER for Injection, USP, due to a Potential Lack of Sterility Assurance

Hospira, Inc., a Pfizer company, is voluntarily recalling BACTERIOSTATIC WATER for Injection, USP, 30 mL, multi-dose vial, lot W20308, to the Hospital/Retail level. Hospira initiated this recall due to lack of confirmation of sterilization for some vials from this lot.

In the event that impacted product is administered to a patient, there is an increased risk that severe adverse events such as invasive bacterial infection, including bacterial meningitis, septicemia, and limited adverse events such as fever, chills, malaise, and cutaneous abscess may occur. To date, Hospira has not received reports of any such adverse events associated with this issue for this lot.

BACTERIOSTATIC WATER for Injection, USP, 30 mL, multi-dose vial is a sterile, nonpyrogenic preparation of water for injection containing 0.9% (9 mg/mL) of benzyl alcohol added as a bacteriostatic preservative. It is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.

BACTERIOSTATIC WATER for Injection, USP, 30 mL, multi-dose vial is packaged as described below. Product was distributed in the U.S. and Puerto Rico to Hospitals/Retailers from March 2018, to April 2018.

NDCLot NumberExpiration DatePresentationConfiguration/Count
Vial: 0409-3977-01 Carton: 0409-3977-03W2030801 DEC 201930 mL, Multiple dose4 x 25 x 30mL vials

Hospira, Inc., places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process. Hospira is notifying its direct customers via a recall letter to arrange for return of any recalled product.

Anyone with an existing inventory of the recalled lot should stop use and distribution and quarantine immediately. Inform Healthcare Professionals in your organization of this recall. For additional assistance, call Stericycle at 1-800-805-3093 between the hours of 8 a.m. to 5 p.m. ET, Monday through Friday.

For clinical inquiries please contact Pfizer using the below information.

ContactContact InformationAreas of Support
Pfizer Medical Information1-800-438-1985, option 3 (9am to 5pm ET Monday through Friday)For Medical questions regarding this product
Pfizer Drug Safety1-800-438-1985, option 1 (24 hours a day 7 days per week)To report adverse events or product complaints

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being executed with the knowledge of the U.S. Food and Drug Administration.

Example of Vial label

vial label

# # # # #

Media Contact:
Kim Bencker
[email protected]
610-329-1340

Sign up for the latest Pfizer Wire news alerts

Receive real-time updates on Pfizer’s news delivered directly to your inbox.

Our Pipeline: Potential Breakthroughs in the Making

We're elevating our breakthroughs in a bold new way. Check out our new visualized product pipeline.

Coronavirus Resources

Learn about SARS-CoV-2, the coronavirus that causes COVID-19, what you can do to stay safe and prevent the spread, and our scientific efforts to help bring an end to the current global health crisis.

Making the COVID-19 Oral Treatment

How 2,000+ Pfizer team members made it happen.

Product Hub

Every product is the result of 1,500 scientists overseeing more than 500,000 lab tests and 30+ clinical trials, all before its first prescription.

Paxlovid Manufacturing B-roll Video

Supplemental video of manufacturing Paxlovid.

Stay up to date on the latest news and alerts through the Pfizer Wire

Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox. 

 

Sign Up Now Details